Only a handful of places left for our September 2026 cohort. Applications close soonApply now →

MSTA
Your future
starts here.

Jessner's solution

Also known as: Jessner peel, Jessner's solution, modified Jessner, MJS

Jessner's solution is 14% resorcinol, 14% salicylic acid and 14% lactic acid in ethanol. It is used alone as a superficial peel and as the keratolytic step before 35% TCA. The modified formula removes resorcinol and adds citric acid.

Evidence status

Moderate

The formulation, the no-neutralisation rule and the Monheit sequence are well documented but rest on expert-consensus/technique literature (International Peeling Society CME, Monheit's own descriptions), not trials. The strongest clinical evidence is for Jessner's as an ADJUNCT to TCA in melasma (one split-face assessor-blinded RCT, n=24, phototypes IV-V; one non-randomised split-face study, n=20) and for Jessner's alone in acne, where one split-face double-blind RCT (n=36) detected no significant difference from 30% salicylic acid — which is not the same as non-inferiority, since no margin was set. A 2020 meta-analysis of 13 comparative studies favours Jessner's over topical hydroquinone in darker skin. All melasma and acne trials are small, short (8-16 weeks), and conducted in Egypt, India and Malaysia — no UK population data. Evidence for the modified (resorcinol-free) formula is thinner still: no primary publication describing its development could be located, and there is no head-to-head trial of classic vs modified Jessner's. Resorcinol's toxicology is well characterised by regulators; its relevance at peel concentrations is not, because we located no regulator assessment of resorcinol for facial-skin application at 14% — a search result, not a proven absence.

What it is#

Jessner’s solution is a combination superficial peel used two ways: alone, and as the keratolytic step that precedes 35% TCA in the Monheit medium-depth peel.

It is also the entry in this encyclopedia where the regulatory position most clearly diverges from what is taught — so that comes first.

The formula, precisely#

Classic Jessner’s solution is 14% resorcinol, 14% salicylic acid and 14% lactic acid in 95% ethanol.[1, 11]

Published statements of that formula are, awkwardly, not internally consistent. One peer-reviewed technique paper gives “14 g of resorcinol, 14 g of salicylic acid, and 14 ml of lactic acid” — mixing grams and millilitres — alongside an obvious units error, “100 mg of 95% ethanol” where 100 mL is meant. Papers also differ on whether they state the basis of the percentage at all.[11, 1, 5]

That matters more than it looks. The accepted pharmaceutical standard is weight-to-volume, and other preparation methods — weight-to-weight, grams per 100 cc water, or diluting from a “saturated = 100%” stock — produce substantially different actual concentrations.[15, 1]

If you compound or dilute anything yourself, the basis of the percentage is not a pedantic detail. It is the difference between the peel you think you are performing and the one you are.

The modified version#

Modified Jessner’s removes resorcinol entirely, raises salicylic acid and lactic acid to 17% each, and adds 8% citric acid.[1, 5]

Note what that means for the composition: the acid load goes up. What changes is which acids are present.

A citation that does not exist

The modification is universally attributed to Bridenstine and Dolezal. We went looking for the primary publication and could not find one.

In the peeling-society review, the attribution carries three references. The name-tag points to a 1994 paper about standardising trichloroacetic acid concentrations that contains nothing about Jessner’s solution, resorcinol or citric acid. The two references that actually support the sentence are an unpublished 2018 conference presentation by one of that review’s own co-authors, and a 2009 melasma study that simply bought the modified solution ready-made.[1, 15]

The formula is real and widely sold. Its published provenance is not what the citation implies.

The stated rationale for removing resorcinol is chemical: resorcinol is meta-dihydroxybenzene and hydroquinone is para-dihydroxybenzene, so resorcinol may cause contact allergy and carries a risk of inducing cross-sensitivity with hydroquinone on repeated exposure.[1]

That is a live concern rather than a theoretical one, because it is precisely the same patients — pigmentation clients — who are often using hydroquinone alongside their peel course. The resorcinol-free formula is preferred in darker skin for exactly that reason, and to avoid pigmentary problems attributed to resorcinol, particularly in phototypes V and VI.[1, 5]

The resorcinol question#

Two separate risks get conflated here, and the frightening one is the less relevant one.

The thyroid story, in proportion

The historical myxoedema reports involved long-term application of resorcinol ointment to damaged, ulcerated skin — chiefly leg ulcers — and the hypothyroidism resolved when exposure stopped. The case reports run from 1950 to 1990, with the bulk from the 1950s and earlier, and no dose-response can be derived from them.[3]

Regulators place the threshold for thyroid effects above 30 mg/kg body weight per day applied dermally to ulcerated skin, and derived a 10 mg/kg/day figure from it with a threefold safety factor — while stating explicitly that there is no evidence intermittent or low-dose resorcinol exposure causes hypothyroidism.[3]

An intact face, a few minutes, a handful of sessions is not that exposure. The regulator states that no dose–response can be derived from those reports, and the >30 mg/kg/day figure is a review-derived hazard threshold rather than a dose measured in each case — and its opinion assesses permitted hair uses, not a 14% facial peel. So this does not establish thyroid risk from a brief facial application, and it does not prove absence either.[3] Do not frighten clients with goitre; do not tell them it is impossible.

The risk that is actually peel-relevant

Contact sensitisation. The best quantified human dataset comes from a French region where a high-concentration resorcinol wart ointment was in use, and it has two separate components that this page previously fused into one sentence.

  • A 20-month consecutive sample: 0.5% of 983 patch-tested patients reacted to resorcinol.
  • A separate case seriesaccumulated over 1992–1999: 24 sensitised patients, of whom 6 of the 17 tested against hydroquinone also reacted — plus 15 of 19 to resorcinol monobenzoate, 9 of 19 to pyrogallol and 7 of 14 to pyrocatechol.[8]

The 24 are not the sensitised subgroup of the 983, and reading them as one dataset inflates both figures. Note also what the hydroquinone finding is: co-sensitisation in people exposed to a wart ointment. It does not show that either chemical induced immunological cross-reactivity to the other. Consider a resorcinol-free product where sensitisation is a concern — but hydroquinone use alone is not an established contraindication.[1]

And it does not always stay where you put it: in that series, 4 of 24 patients had generalised urticaria and 6 had a generalised papulo-vesicular rash with pompholyx.[8]

Keep it in proportion in the other direction too. Resorcinol contact allergy is described as rare and possibly under-reported; regulators classify it as a moderate skin sensitiser on animal data while noting a low frequency of clinical sensitisation in humans — though an earlier committee graded it a strong sensitiser.[1, 3]

UK regulatory position#

The part nobody teaches, stated precisely.

Under the UK Cosmetics Regulation, resorcinol is an Annex III restricted substance, permitted only in oxidative hair dye and eyelash-colouring products — where the concentration applied after mixing must not exceed 1.25% — and in hair lotions and shampoos at 0.5%. There is no permitted cosmetic use on facial skin at any concentration.[2]

It follows that a 14% resorcinol solution intended for facial application cannot lawfully be placed on the Great Britain market as a cosmetic product. Northern Ireland applies the current EU Annex III under the Windsor Framework and should be checked against that text rather than assumed to match — this page said “the UK” throughout until August 2026, which collapsed two regimes.[2]i

We also searched for a regulator assessment of resorcinol on intact facial skin at peel concentrations and found none. That is the result of our search. It is not proof that no regulator anywhere has ever assessed such a use, which is what this page previously asserted.[no source found]

We are stating the Annex position and the inference the Annex text supports, and stopping there. What that means for any particular product you have been sold, and for your own position in supplying or using it, is a question for your supplier, your insurer and — if the answer is unsatisfactory — your own legal advice. It is not a question this entry can answer for you.

Separately, on scope of practice: no licensing scheme for non-surgical cosmetic procedures is in force in England. The 2023 consultation closed in October 2023, the August 2025 government response did not assign individual procedures to risk tiers, and secondary legislation must still pass through Parliament.[14]

Technique and endpoints#

Jessner’s solution and modified Jessner’s do not require neutralisation, unlike glycolic and pyruvic acid peels, which must be neutralised with sodium bicarbonate or removed with water.[1]

Frosting is graded in three levels: level I a light reticular frost with background erythema; level II a confluent light white frost with background erythema; level III a solid white frost without erythema. With TCA, that frost is epidermal and dermal protein denaturation.[1]

But whose frost is it?

With salicylic acid in an ethanol vehicle, the whitening described at 20–30% is a pseudofrost — crystallised salicylic acid on the surface as the ethanol evaporates, which cannot penetrate.

Jessner’s carries salicylic acid at 14%, below the concentration at which that is described, so how much of any Jessner’s whitening is crystal rather than denaturation is not established. And one melasma study reported that modified Jessner’s produced no frost of its own at all.[1, 5]

Practical consequence: for Jessner’s alone, aim for erythema with a light reticulate frost, and do not chase a solid frost you may not be able to interpret.

The Monheit sequence#

The reason Jessner’s matters most in practice.

The face is degreased with acetone, Jessner’s solution is applied as a keratolytic until a reticulate frost is obtained, and 35% TCAfollows. The Jessner’s step induces epidermolysis so that the TCA penetrates evenly and predictably — the combination replaced the historical practice of using 50% TCA alone, which gave uneven penetration, erosions, post-inflammatory hyperpigmentation and scarring.[1, 12, 11]

Two steps, weaker acid, better control. That is the whole design principle, and it is why a “stronger single agent” instinct is the wrong one here.

Note the TCA strength. Jessner’s plus 20% TCA is used in practice but may not create a significant medium-depth wound, and the combination at that strength is described in the peeling literature as unstudied.[1]

What it treats#

Melasma — studied both alone and as an adjunct, all short-term

In a split-face, assessor-blinded randomised trial of 24 women with phototypes IV–V, six fortnightly sessions of Jessner’s plus 20–25% TCA produced a significantly lower MASI than 20–25% TCA alone — at the cost of greater immediate discomfort, with no significant difference in post-inflammatory hyperpigmentation.[4, 1]

A smaller non-randomised split-face study in 20 women found adding modified Jessner’s to 15% TCA gave a 71.7% MASI reduction versus 54.3% for TCA alone — with discomfort reported by 80% on the combined side versus 20% on the TCA-only side.[5]

Against topical hydroquinone in darker skin, a meta-analysis of 13 comparative studies favoured Jessner’s, with a mean MASI difference of −3.20 (95% CI −5.35 to −1.05, P = 0.004) — though how many of those 13 studies contributed to the Jessner’s comparison specifically is not reported.[6]

But it is not the strongest single agent.In a three-arm randomised study of 45 patients, TCA 20% alone gave a significantly lower MASI than Jessner’s alone at 16 weeks (P = 0.035).[13]

Acne in skin of colour

A double-blind split-face randomised trial in 36 patients, 94.5% of them phototype IV–V, found three fortnightly Jessner’s peels no different from 30% salicylic acid, with both significantly improving lesion counts and pigmentation from baseline.[7]

Actinic keratoses

In a 15-person split-face comparison with no randomisation described, no difference was detected between a single Jessner’s plus 35% TCA peel and three weeks of twice-daily 5% fluorouracil for widespread facial actinic keratoses in a 15-patient split-face study — both reduced visible lesions by 75% with equivalent histological improvement over 12 months.

The follow-up is the useful part: lesion counts had risen again between 12 and 32 months in both arms, with only 8 of the 15 patients still available for assessment.[9, 10]

Actinic keratoses are a medical diagnosis and their management is not a skincare professional’s remit. It is on the page because it is the clearest available demonstration that a peel result is a snapshot, not a cure.

In professional practice#

  • Ask your supplier whether your Jessner’s contains resorcinol, and what its regulatory status in the UK is. The answer should be specific.
  • Consider the resorcinol-free formula where sensitisation is a concern — in darker skin, and where a client is already using hydroquinone. Hydroquinone use alone is not an established contraindication, and the human data show co-sensitisation rather than proven cross-reactivity.[1]
  • Do not neutralise. Neither formula requires it.
  • Aim for erythema with light reticulate frostwhen using Jessner’s alone. A solid frost is not the target and may not even be denaturation.
  • Know the basis of your percentagesif you dilute anything — though note that the weight-to-volume recommendation comes from a paper that tested TCA solutions only and says nothing about Jessner’s.[15, 1]
  • Know that the melasma evidence is short-term either way — and warn about discomfort, which is where the combined protocols consistently pay.
  • The Monheit peel is 35% TCA.Jessner’s plus 20% is a different, unstudied thing.

What remains uncertain#

  • Whether the modified formula is genuinely safer in darker skin. It is a rationale, not a demonstrated finding — no head-to-head trial of classic versus modified exists.
  • The provenance of the modified formula itself. No primary publication could be located.
  • How much of any Jessner’s frost is protein denaturation rather than crystallised salicylic acid.
  • Systemic salicylate exposure after a full-face Jessner’s peel. No study has measured it, so the often-repeated caution rests on pharmacological reasoning rather than data.[no source found]
  • Whether resorcinol at peel concentrations on intact facial skin carries any systemic risk at all. No regulator has assessed it for that use.
  • Whether any of this transfers to a UK clientele — every melasma and acne trial was conducted in Egypt, India or Malaysia.

Common misconceptions#

“Jessner’s needs neutralising.”

It does not. Both formulas sit among the peels that do not require neutralisation, alongside tretinoin and salicylic acid.[1]

“Modified Jessner’s is a weaker Jessner’s.”

Nobody has compared them head to head, so neither “gentler” nor “stronger” is established. On composition, salicylic and lactic go up from 14% to 17%. Resorcinol is removed and 8% citric acid added.[1, 5]

“Resorcinol in a peel will damage the thyroid.”

The myxoedema evidence is pre-1973 case reports of prolonged application to ulcerated leg skin above 30 mg/kg/day, reversing on stopping. Regulators state there is no evidence intermittent exposure causes hypothyroidism.[3]

“Jessner’s plus 20% TCA is a medium-depth peel.”

It may not create a significant medium-depth wound, and at that strength the combination is described as unstudied. The Monheit peel is 35%.[1]

“Bridenstine and Dolezal published the modified formula.”

The citation given is a 1994 paper about standardising TCA that never mentions Jessner’s, resorcinol or citric acid.[1, 15]

“Jessner’s is the best peel for melasma.”

A meta-analysis puts it ahead of topical hydroquinone, but TCA 20% alone beat Jessner’s alone in a randomised three-arm study.[13]

Frequently asked questions#

Should I be using classic or modified Jessner’s?

No head-to-head trial compares them, so neither is established as gentler or safer. Where sensitisation is a concern — darker skin, or a client already using hydroquinone — the resorcinol-free formula has a reasonable rationale, though the human data show co-sensitisation rather than proven cross-reactivity.[1, 5] In Great Britain there is also the Annex III position on resorcinol to take up with your supplier.

What endpoint am I looking for?

Erythema with a light reticulate frost for Jessner’s alone. In the Monheit sequence, reticulate frost is the signal to move to the TCA step.[1, 12, 11]

Is a full-face Jessner’s a salicylate risk?

Nobody has measured it. The caution is pharmacological reasoning, not data — which is a reason to keep it in mind, not a reason to quote a number.[no source found]

Why does my solution look different from the published formula?

Possibly the basis of the percentage. Weight-to-volume is the standard, and other methods produce substantially different actual concentrations from the same stated number.[15, 1]

How long do melasma results last?

Unknown from the evidence here. The melasma studies followed participants for eight to sixteen weeks, so nobody has measured durability.[4, 5, 10]i This page previously answered with actinic-keratosis data, which is a different indication in a different cohort and cannot answer a melasma question. For what it is worth, that actinic keratosis data — a different indication, but the longest follow-up available — show lesion counts rising again between 12 and 32 months.[9, 10]

References#

Each source is graded by evidence tier. Tier 4 material (manufacturer documents, expert consensus, practitioner experience) is useful for protocol and context, and is never presented as equivalent to independent clinical evidence.

  1. Lee KC, Wambier CG, Soon SL, Sterling JB, Landau M, Rullan P, Brody HJ; International Peeling Society. Basic chemical peeling: Superficial and medium-depth peels. J Am Acad Dermatol. 2019 Aug;81(2):313-324.Tier 4Supports: Full text read. Verbatim: 'JS consists of 14% resorcinol, 14% SA, and 14% lactic acid (LA) in 95% ethanol.' On the modification: 'Resorcinol, which acts similarly to hydroquinone (meta- and para-dihydroxybenzene, respectively), may cause contact allergy and risks inducing cross-sensitivity with hydroquinone with repeated exposure. In response, Bridenstine and Dolezal[16] modified MJS by increasing the concentration of SA and LA to 17% and replacing resorcinol with 8% citric acid.' Key point box: 'Tretinoin, salicylic acid, Jessner solution, and modified Jessner solution do not require neutralization / Glycolic and pyruvic acid require neutralization.' Monheit peel described as 'degreasing the face with acetone followed by the application of JS until a reticulate frost is obtained', then TCA 35%; also 'MJS can be used alternatively in darker skin to treat pigmentation and has less risk of contact sensitivity' and 'Although contact allergy to resorcinol is rare, it may be underreported.' Critically: 'JS plus TCA 20% may be used, but may not create a significant medium-depth wound and is unstudied.' Three frost levels defined: 'There are 3 levels of frosting: 1) a light reticular frost with background erythema, 2) a confluent light white frost with background erythema, and 3) a solid white frosting without erythema.' On melasma: 'A study comparing JS plus 20% TCA versus 20% TCA alone in individuals with higher Fitzpatrick skin phototypes found that JS plus 20% TCA was more effective in treating melasma but with greater immediate discomfort. There was no significant difference in PIH.' Also notes salicylic acid 20-30% in ethanol 'crystallizes upon ethanol evaporation, yielding a pseudofrost'. SCOPE LIMIT: a CME narrative/expert-consensus article, not a systematic review; it carries no formal evidence grading and its own citation for the modified-Jessner attribution does not support that claim (see source 15).Funding / interest: Journal-based CME. The disclosure block states: authors, editors, content validation/peer reviewers and planners 'have reported no relevant financial relationships with commercial interest(s).' Written on behalf of the International Peeling Society, a specialty society, not a manufacturer.
  2. Commission Regulation (EU) No 1197/2013 of 25 November 2013 amending Annex III to Regulation (EC) No 1223/2009 on cosmetic products — entry 22 (Resorcinol). Retained in UK law; text as published on legislation.gov.uk.Tier 1Supports: Full retained text read directly. Annex III entry 22 is replaced by: '22 | 1,3-benzenediol | Resorcinol | 108-46-3 | 203-585-2 | (a) Hair dye substance in oxidative hair dye products ... (b) Products intended for colouring eyelashes ... For (a) and (b): After mixing under oxidative conditions the maximum concentration applied to hair or eyelashes must not exceed 1,25 % ... (b) For professional use only ... (c) Hair lotions and shampoos (c) 0,5 % (c) Contains resorcinol.' Mandatory label warnings include 'Do not use to dye eyelashes or eyebrows' (for hair dye), 'This product is not intended for use on persons under the age of 16', and 'This product can cause severe allergic reactions'. SCOPE LIMIT: this governs resorcinol in COSMETIC PRODUCTS placed on the market. It does not itself prohibit a practitioner using a compounded professional preparation, and it does not represent a toxicological assessment of 14% resorcinol on facial skin — no such assessment exists.
  3. Scientific Committee on Consumer Safety (SCCS). Opinion on Resorcinol (CAS No 108-46-3, EC No 203-585-2). SCCS/1619/20. Preliminary version 16 October 2020; final version 30-31 March 2021. European Commission.Tier 1Supports: 39-page PDF downloaded and read. CONCLUSION verbatim: 'Keeping in view the evidence on endocrine disrupting properties of resorcinol, the SCCS assessment shows that resorcinol is safe when used as an oxidative hair dye in products intended for hair and eyelashes up to 1.25 % and up to 0.5 % in hair lotions and shampoos.' And: 'Resorcinol is a moderate skin sensitiser based on data from animal studies. Clinical studies show that the frequency of contact sensitisation in humans is low.' Note the earlier SCCS position was harsher: 'According to the grading scheme used by the SCCS (SCCP/0919/05), resorcinol should be considered as a strong sensitizer' (from SCCS/1270/09), with an LLNA EC3 of 1.4% calculated by the study authors. On myxoedema, quoting the Danish CEHOS 2012 evaluation: 'according to human case reports, resorcinol indeed exerts antithyroid functions. Data are old (all from before 1973), but quite clear: long-term administration of resorcinol to permeable (damaged) skin can cause myxoedema (reduced thyroid function). Cessation of exposure causes the myxoedema to disappear.' Dose context: 'thyroid effects may occur as a result of dermal exposure to ulcerized skin at resorcinol dose levels greater than 30 mg/kg bw/day. From these data, a thyroid effect threshold value of 10 mg/kg bw/day for dermal exposure was established... However, high-dose exposure has been rare in the past and has occurred mainly in patients as a result of the treatment of ulcers with large amounts of Resorcinol for a long period of time. Based on Lynch et al. (2002), there is no evidence that intermittent or low-dose exposure to Resorcinol causes hypothyroidism or any other adverse health effects.' Section 3.4.9 'Human data' is EMPTY — no human data were submitted. Resorcinol is classified eye irritation cat 2 (H319) and skin irritation cat 2 (H315). SCOPE LIMIT: assesses hair products only; thyroid data are predominantly rodent, and the human myxoedema evidence is pre-1973 case reports of prolonged ointment application to ulcerated legs, not facial peels.Funding / interest: European Commission scientific committee. The dossier was submitted by an industry applicant (hair-dye sector); the opinion repeatedly cites 'the applicant' re-evaluating sensitisation data, so the underlying data package is manufacturer-supplied even though the assessment is independent.
  4. Abdel-Meguid AM, Taha EA, Ismail SA. Combined Jessner Solution and Trichloroacetic Acid Versus Trichloroacetic Acid Alone in the Treatment of Melasma in Dark-Skinned Patients. Dermatol Surg. 2017 May;43(5):651-656.Tier 2Supports: Abstract read in full via PubMed. Design: 'split face, right-left, assessor-blinded, randomized controlled study.' Population: '24 adult female patients (skin phototypes IV-V) with bilateral melasma'. Intervention: 'combined trichloroacetic acid (TCA) (20%-25%) and Jessner's solution versus TCA (20%-25%) alone', 6 sessions at 2-week intervals. Outcome: MASI plus photography. Results: 'Both therapeutic modalities showed significant decrease in MASI score, which was significantly lower on the side treated with both Jessner solution and TCA. There were significant negative correlations between the percentage of improvement of MASI score and both age of the patients and duration of the melasma.' Conclusion: 'combined Jessner solution and TCA is more effective.' SCOPE LIMITS: n=24, single centre (Assiut, Egypt), phototypes IV-V only, TCA range 20-25% not fixed at 20%, no effect size or p-values in the abstract, no long-term follow-up reported, full text not accessed so exact MASI figures and funding/COI statements are unverified. Note this study attracted a published commentary (Brody HJ, Dermatol Surg 2017;43:657) and a further Comment in 2018.
  5. Safoury OS, Zaki NM, El Nabarawy EA, Farag EA. A study comparing chemical peeling using modified Jessner's solution and 15% trichloroacetic acid versus 15% trichloroacetic acid in the treatment of melasma. Indian J Dermatol. 2009;54(1):41-45.Tier 3Supports: Full text read. Formula verbatim from Methods: 'Modified Jessner's solution (Delasco) preparation was formed with 8% citric acid (weight to volume), 17% lactic acid (weight to volume), 17% salicylic acid (weight to volume), and ethanol anhydrous' (the Discussion instead says 'in ethanol 95%'). Population: 20 married females, epidermal melasma only (Wood's light confirmed), mean age 38.25 years, all skin type III or IV, melasma duration mean 7.6 years. Design: split-face by SIDE not randomised — '15% TCA was applied to the whole face, with the exception of the left malar area to which combined TCA 15% and modified Jessner's solution was applied'; MJS applied 'until the appearance of erythema', TCA 'until frosting'; up to 8 sessions every 10 days; 8-week follow-up. Results: right (TCA only) MASI 4.460 ± 1.571 → 2.040 ± 1.326 post-treatment (54.26% decrease, P=0.000), 2.270 ± 1.400 at follow-up (49.1% decrease). Left (TCA + MJS) 4.350 ± 1.468 → 1.230 ± 0.808 (71.72% decrease, P=0.000), 1.670 ± 1.175 at follow-up (61.6% decrease). Between-side comparison P=0.000 post-peel, P=0.002 at follow-up. Side effects: discomfort 16/20 (80%) on the MJS side vs 4/20 (20%) TCA-only, P<0.01; PIH 2/20 (10%) TCA-only vs 0/20 combined, P>0.05 (non-significant); swelling, erythema and folliculitis/acne equal in both. Rationale stated verbatim: 'We also used modified Jessner's solution (lactic acid 17%, salicylic acid 17%, and citric acid 8% in ethanol 95%) without resorcinol, instead of the classic Jessner's solution, to avoid possible allergic reactions and hyperpigmentation problems, which may be created by resorcinol, especially in skin types V and VI.' Also notes blinding was impossible 'because of the very characteristic odor and the absence of frost in the modified Jessner's solution.' SCOPE LIMITS: n=20, not randomised (MJS always on the left malar area), unblinded, epidermal melasma only, 15% TCA not 20%, 8-week follow-up only.Funding / interest: Stated in paper: 'Source of Support: Nil. Conflict of Interest: Nil.'
  6. Dorgham NA, Hegazy RA, Sharobim AK, Dorgham DA. Efficacy and tolerability of chemical peeling as a single agent for melasma in dark-skinned patients: A systematic review and meta-analysis of comparative trials. J Cosmet Dermatol. 2020 Nov;19(11):2812-2819.Tier 1Supports: Abstract read in full. Included '10 RCTs and three prospective comparative studies (No. of patients = 478)' of chemical peels as single agents for facial melasma in darker skin types. Relevant pooled result verbatim: 'The overall effect estimates favored trichloroacetic acid peel (MD -5.30, 95% CI [-6.41, -4.19], P < .001) and Jessner's solution (MD -3.20, 95% CI [-5.35, -1.05], P = .004) over topical hydroquinone in terms of MASI.' Also: glycolic acid favoured over TCA (MD -1.89, 95% CI -3.26 to -0.52, P=.007); GA not favoured over tretinoin, vitamin C iontophoresis or amino fruit acid. Conclusion: 'chemical peelings are effective as single agents for management of melasma in patients with darker skin types, with the use of topicals as maintenance treatment.' SCOPE LIMITS: the Jessner's-vs-hydroquinone estimate rests on a small subset of the 13 included studies (number not stated in the abstract); heterogeneity, risk-of-bias assessment and follow-up duration not available from the abstract; full text not accessed.
  7. How KN, Lim PY, Wan Ahmad Kammal WSL, Shamsudin N. Efficacy and safety of Jessner's solution peel in comparison with salicylic acid 30% peel in the management of patients with acne vulgaris and postacne hyperpigmentation with skin of color: a randomized, double-blinded, split-face, controlled trial. Int J Dermatol. 2020 Jul;59(7):804-812.Tier 2Supports: Abstract read in full. Design: 'randomized double-blinded, split-face, controlled trial'; 36 subjects, '94.5% Fitzpatrick Type IV-V', Malaysia. Each side randomly assigned to Jessner's solution or salicylic acid 30%; treated 'once fortnightly for a total of three sessions'. Outcomes: lesion counts, Michaelsson acne score, photographs, postacne hyperpigmentation index. Results: 'significant reduction in inflammatory, noninflammatory lesions, MAS, and PAHPI scores (P < 0.001, respectively) were noted in comparison to baseline. Mixed model analysis revealed no significant outcome difference between the two groups. Patients who reported good and very good outcome were 76.4% (JS) and 85.3% (SA). Burning, stinging sensation, and exfoliation were the common complications reported. Postinflammatory hyperpigmentation was reported only once in the JS arm.' Conclusion: 'Both JS and SA were equally effective.' SCOPE LIMITS: n=36, only three sessions, no long-term follow-up, equivalence inferred from a non-significant difference in a small trial (not a formal non-inferiority design); funding/COI not verified.
  8. Barbaud A, Reichert-Penetrat S, Trechot P, Granel F, Schmutz JL. [Sensitization to resorcinol in a prescription verrucide preparation: unusual systemic clinical features and prevalence]. Ann Dermatol Venereol. 2001 May;128(5):615-618. [Article in French]Tier 3Supports: Abstract read in full. Setting: Lorraine, France, where resorcinol was used in high concentration in an anti-wart ointment. Two components: (a) case series of all patients sensitised to resorcinol 1992-1999 (n=24); (b) prevalence — 'Over a 20-month period, 983 consecutive patients underwent our standard patch tests where we included resorcinol (1 p. 100 in petrolatum)... Sensitization to resorcinol was observed in 0.5 p. 100 of the 983 consecutively tested patients.' Clinical picture in the 24: 'All developed contact eczema on the site of application of the ointment, with generalized urticaria (4 cases), pompholyx (1 case), and generalized papulo-vesicular rash with pompholyx (6 cases).' Co-reactivity, with denominators: 'Positive patch tests were observed with resorcinol monobenzoate (15/19 cases), pyrocatechol (7/14 cases), pyrogallol (9/19 cases), salicylaldehyde (2/17 cases), and hydroquinone (6/17 cases). Negative patch tests were observed with phenysalicylate, hexylresorcinol, or fluoresceine.' Conclusion verbatim: 'Resorcinol should not be applied in high concentrations as it can provoke generalized sensitization and co-sensitization with other pro-haptens.' SCOPE LIMITS: this is the only quantified human dataset I could locate linking resorcinol and hydroquinone reactivity. It is a single-region series driven by one high-concentration wart ointment, not by peels; the authors describe CO-sensitisation (both haptens positive), which is not the same as proven cross-reactivity; the hydroquinone denominator is only 17 patients; French-language abstract only, full text not accessed.
  9. Lawrence N, Cox SE, Cockerell CJ, Freeman RG, Cruz PD Jr. A comparison of the efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Arch Dermatol. 1995 Feb;131(2):176-181.Tier 3Supports: Abstract read in full via PubMed. Design: controlled split-face clinical trial. Population: 'Fifteen patients with severe facial actinic damage and comparable numbers of lesions on both sides of the face'. Left side received a single application of Jessner's solution plus 35% TCA; right side received 5% fluorouracil cream twice daily for 3 weeks. Assessments before treatment and at 1, 6 and 12 months, with visible lesion counts and random skin biopsies. Results: both treatments reduced visible actinic keratoses by 75% and produced 'equivalent reductions in keratinocyte atypia, hyperkeratosis, parakeratosis, and inflammation'. Minimal side effects with the peel; most patients preferred the peel for 'the single application and less morbidity'. SCOPE LIMITS: n=15, single centre, no randomisation described, 12-month horizon; this is the medium-depth Monheit combination (JS + 35% TCA), NOT Jessner's alone.
  10. Witheiler DD, Lawrence N, Cox SE, Cruz C, Cockerell CJ, Freemen RG. Long-term efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Dermatol Surg. 1997 Mar;23(3):191-196.Tier 3Supports: Abstract read in full. Extended follow-up of the same 15-patient cohort as source 9; only 8 patients available for reevaluation at 32 months. Assessments at 1, 6, 12 and 32 months. Results: both approaches showed 'a reduction in mean number of AK at 12 months followed by an increase in mean AK number between 12 and 32 months'; biopsies showed improvement in keratinocytic atypia, hyperkeratosis, parakeratosis and inflammation at all timepoints with both treatments. Three squamous cell carcinomas developed after treatment — one on the peel-treated side, two on the fluorouracil-treated side. Recommendation: 'reevaluation yearly or every 1.5 years for reappearance of AK and retreatment'. SCOPE LIMITS: 8 of 15 retained at 32 months — high attrition; this is an honest negative on durability, not a failure signal specific to the peel.
  11. Dayan E, Rohrich RJ. Jessner's solution with trichloroacetic acid chemical peel: optimizing outcomes and safety. Plastic and Reconstructive Surgery — Global Open. 2019;7(5):e2250.Tier 4Supports: Full text read via Europe PMC. Describes the senior author's own protocol. Composition verbatim: 'In our practice, the Jessner's solution is premixed by a pharmacist and contains 100 mg of 95% ethanol, 14 g of resorcinol, 14 g of salicylic acid, and 14 ml of lactic acid.' NOTE: '100 mg of 95% ethanol' is plainly a units error for 100 mL — corroborating evidence that even peer-reviewed descriptions of this formula carry transcription errors. Elsewhere it defines light peels as including 'Jessner's solution (resorcinol, salicylic acid, lactic acid, and ethanol)'. Technique: four labelled glasses — 70% ethyl alcohol, acetone, Jessner's solution, 35% TCA; cleanse with alcohol, degrease with acetone, air dry, then 'One to four layers of Jessner's solution is applied to the face with the endpoint being uniform areas of erythema with slight areas of frost'; 'In patients with thick sebaceous skin, more coats of Jessner's may be required'; then 35% TCA. Depth: 'a medium-depth peel into the upper reticular dermis'; 'Typically, 7-10 days are needed for skin to slough and reepithelialize. Dermal regeneration takes up to 6 weeks.' Frost depth attributed to the Dolezal classification. No neutralisation step is described anywhere in the protocol. Pretreatment: 4-6 weeks of tretinoin 0.05-0.1%, hydroquinone 2-4%, sunscreen and AHA 4-10%; aciclovir 2 days before to 5 days after in patients with a herpes history. SCOPE LIMIT: single-practice technique paper with no patient data, no outcomes and no comparator.Funding / interest: Disclosed in the article: Dr Rohrich receives royalties and holds consulting relationships with multiple companies; Dr Dayan founded wikiPlasticSurgery.com and serves as a Key Opinion Leader for InMode Aesthetic Solutions. No product-specific sponsorship of this paper stated.
  12. Monheit GD. The Jessner's + TCA peel: a medium-depth chemical peel. J Dermatol Surg Oncol. 1989 Sep;15(9):945-950. (See also Monheit GD. The Jessner's-trichloroacetic acid peel. An enhanced medium-depth chemical peel. Dermatol Clin. 1995;13(2):277-283; and Monheit GD. Medium-depth chemical peels. Dermatol Clin. 2001;19(3):413-425.)Tier 4Supports: PubMed records read for all three papers; full texts not accessible. The 1989 paper is the origin citation for the combination: 'The Jessner's + TCA peel, a method of chemexfoliation, is a combination of two acidic compounds. It has been found to be an effective peeling procedure that produces a medium-depth peel for photoaging skin, actinic keratoses, and rhytides.' The 1995 paper states: 'The Jessner's-trichloroacetic acid (TCA) peel is a procedure developed by Monheit to produce a safe, effective medium-depth chemical peel for the treatment of photoaged skin, actinic keratoses, and superficial acne scars. The technique of pretreatment degreasing and combination chemicals allow a deeper penetration for the 35% TCA, increasing its efficacy while preserving its safety.' The 2001 paper: 'The combination medium-depth chemical peel (Jessner's solution +35% TCA) has been accepted as a safe, reliable, and effective method for the treatment of moderate photoaging skin.' SCOPE LIMIT: these are technique descriptions with no comparative data; only the abstracts were verified. The eponym 'Monheit peel' and the 35% TCA figure trace to these.
  13. Azzam OA, Leheta TM, Nagui NA, Shaarawy E, Hay RM, Hilal RF. Different therapeutic modalities for treatment of melasma. J Cosmet Dermatol. 2009 Dec;8(4):275-281.Tier 2Supports: Abstract read in full. 45 patients with melasma 'randomly assigned into three groups of fifteen patients each': group A Jessner's solution peel, group B TCA 20% peel, group C topical hydroquinone 2% + kojic acid. Follow-up at 16 weeks. Results: after treatment MASI was significantly lower in A than C (P=0.01) and in B than C (P<0.001), with 'no statistically significant difference between groups A and B'. After the follow-up period: A lower than C (P<0.001), B lower than C (P<0.001), and 'statistically significantly lower in group B than group A (P = 0.035)'. Conclusion: 'Trichloroacetic acid 20% showed better results than Jessner's solution as peeling agent and hydroquinone 2% with kojic acid as a topical agent in the treatment of melasma.' This is a useful counterweight: Jessner's ALONE was beaten by TCA 20% alone at follow-up. SCOPE LIMITS: 15 per arm, single centre (Cairo), no blinding described, 16-week horizon, funding/COI not verified.
  14. Department of Health and Social Care. Licensing of non-surgical cosmetic procedures (consultation and government response). GOV.UK. Consultation 2 September – 28 October 2023; government response published 7 August 2025.Tier 1Supports: Page read. Consultation ran from 9am 2 September 2023 to 11:59pm 28 October 2023. Government response published 7 August 2025. The response does NOT assign individual procedures to specific tiers — it states that further work is needed to determine specific procedures' classification within the scheme. The scheme is not yet in force: the government committed to introduce restrictions through secondary legislation, which requires Parliamentary process before the legal restrictions or licensing regulations can be introduced. Three strands set out: classifying high-risk procedures (e.g. liquid Brazilian butt lifts) as CQC-regulated activities; developing local authority licensing for lower-risk procedures; and introducing age restrictions. A further public consultation on high-risk procedures was signalled. SCOPE LIMIT: England only; chemical peels are not individually classified anywhere in the published response.
  15. Bridenstine JB, Dolezal JF. Standardizing chemical peel solution formulations to avoid mishaps: great fluctuations in actual concentrations of trichloroacetic acid. Journal of Dermatologic Surgery and Oncology. 1994;20(12):813–816.Tier 3Supports: Abstract read in full. This is the paper cited (as reference 16) by the JAAD CME article as the source for 'Bridenstine and Dolezal modified MJS'. Its actual content is entirely about TCA: it compares four methods of preparing TCA solutions (weight/volume; weight/weight; grams of TCA in 100 cc water; saturated TCA called 100% then diluted), converts each to w/v, and finds 'Tremendous variations were found in the relative concentrations of TCA in these solutions. To avoid mishaps and complications, the wt/vol method should be used.' It contains NOTHING about Jessner's solution, resorcinol or citric acid. Cited here as evidence that the standard attribution of the modified Jessner formula has a broken citation trail. Separately, this paper is the origin of the w/v standard for peel solutions, which matters when reading any '%' on a peel bottle. Author note: Dolezal founded the compounding supplier Delasco, which markets Modified Jessner's — a commercial connection relevant to the attribution.

Continue learning with MSTA#

Skinipedia is written by the educators at MSTA, the medic-led skincare training academy in Liverpool.